CG oncology, Inc. (CGON)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$64.80-4.30%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CGON
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -14.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
CGON — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, CG Oncology, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Ac…
Why it matters: These results test a drug combination in high-risk patients. Clear benefit could support more study of this approach.
Watch forCG Oncology reports lasting tumor control in Cohort CX. No safety issue limits treatment.
Also watch forCG Oncology reports weak or brief tumor control, or a safety issue that limits treatment.
Why it matters: This trial tests cretostimogene in intermediate-risk bladder cancer. Its results can show whether the treatment helps this group.
Watch forThe topline release says the trial met its primary endpoint. It reports no new safety concerns.
Also watch forThe release reports that the trial missed its primary endpoint or found a safety issue that limits use.
Why it matters: The company says its cash can fund operations through 2029. Faster cash use could put planned trial and filing work under pressure.
Worry ifA company update says cash is too low to fund operations through 2029, or gives a shorter runway.
Less concerning ifCash remains near or above $1.0 billion. Management again says it can fund operations through 2029.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$189 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $472 loss on $10,000 · 4.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,741 loss on $10,000 · 27.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.